

**PRESS RELEASE:**

**SES ESG RELEASES ESG RATING FOR AKUMS DRUGS AND PHARMACEUTICALS LIMITED**

**February 18, 2026** – SES ESG Research Pvt. Ltd. has released the ESG Rating Report for Akums Drugs and Pharmaceuticals Limited based on available data for FY 2024-25.

<b>ESG RATING</b>		
<b>RATING AGENCY- SES ESG RESEARCH PVT LTD.</b>		
<b>Company</b>	<b>ISIN</b>	<b>2025</b>
Akums Drugs and Pharmaceuticals Limited	INE09XN01023	58.8

For detailed information on the report, write to: [infoesg@sesgovernance.com](mailto:infoesg@sesgovernance.com)

**About:** SES ESG Research Private Limited (**SES ESG**) is a wholly owned subsidiary of Stakeholders Empowerment Services (**SES**), a not-for-profit and independent entity. It was established to meet SEBI regulations for ESG Rating Providers (ERP) and is registered as a Category II ERP with SEBI (Registration No.: IN/ERP/Category-II/0002) as 'Subscriber Pay' Model, effective 25<sup>th</sup> April, 2024.

Originally, the ESG rating business was conducted under SES, which pioneered ESG ratings in India since 2018-19 and published its first ESG report in 2019. SES ESG now covers over 720+ companies, with coverage expanding based on client demand. SES has undertaken significant ESG work for both domestic and international clients since 2019.

SES - Holding Company is a not for profit, absolutely independent conflict free entity, very different from any other vendors as far as structure goes.